Case reports in neurology · 2025
First Reported Case of Ocrelizumab-Associated Leukocytoclastic Vasculitis in Primary Progressive Multiple Sclerosis: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nahayati Mohammadali, Farahnezhad Mina, Khanmirzaei Amir, Khosravani Fatemeh
Аннотация
BACKGROUND: Leukocytoclastic vasculitis (LCV) is a small vessel vasculitis primarily affecting the skin, and its association with specific drugs is not widely documented. This case study explores the occurrence of LCV following the initiation of ocrelizumab, a monoclonal antibody used in the treatment of primary progressive multiple sclerosis (PPMS).
CASE PRESENTATION: A 49-year-old Iranian female with PPMS developed lower limb edema and diffuse palpable purpura 1 week after starting ocrelizumab therapy. Skin biopsy confirmed LCV, showing vessel wall destruction, neutrophil infiltration, and fibrinoid necrosis. Laboratory tests revealed elevated inflammatory markers, including ESR 1 h: 52 and CRP: 52.8, supporting the diagnosis. The patient's symptoms improved after a course of intravenous methylprednisolone, and ocrelizumab was resumed without recurrence of skin lesions. This case highlights the need for vigilance in detecting drug-related vasculitis in ocrelizumab-treated patients.
CONCLUSION: This case is the first reported instance of LCV associated with ocrelizumab in the treatment of multiple sclerosis. It underscores the need for awareness of potential drug-induced vasculitis in patients undergoing new or modified treatments and contributes to the growing understanding of adverse effects associated with ocrelizumab.
CASE PRESENTATION: A 49-year-old Iranian female with PPMS developed lower limb edema and diffuse palpable purpura 1 week after starting ocrelizumab therapy. Skin biopsy confirmed LCV, showing vessel wall destruction, neutrophil infiltration, and fibrinoid necrosis. Laboratory tests revealed elevated inflammatory markers, including ESR 1 h: 52 and CRP: 52.8, supporting the diagnosis. The patient's symptoms improved after a course of intravenous methylprednisolone, and ocrelizumab was resumed without recurrence of skin lesions. This case highlights the need for vigilance in detecting drug-related vasculitis in ocrelizumab-treated patients.
CONCLUSION: This case is the first reported instance of LCV associated with ocrelizumab in the treatment of multiple sclerosis. It underscores the need for awareness of potential drug-induced vasculitis in patients undergoing new or modified treatments and contributes to the growing understanding of adverse effects associated with ocrelizumab.